Supported by its pharmacodynamic effects (inhibition of phosphorylation of mTOR pathway proteins such as AKT, ribosomal S6, and 4EBP1) development of P7170 provides an attractive opportunity as a treatment option for NSCLC. Here, EIF4EBP1 is linked to non-small cell lung carcinoma.